Description

Tirzepatide 10mg: Dual-Action GLP-1 & GIP Agonist

Tirzepatide is a powerhouse “dual agonist” that revolutionized metabolic research. Known as a twincretin, it is the first peptide to successfully combine GLP-1 and GIP receptor activation, offering superior results compared to single-hormone treatments like Semaglutide.

Why Research Tirzepatide?

• Dual-Pathway Synergy: Mimics two natural incretin hormones to optimize insulin sensitivity and glucose metabolism.

• Proven Efficacy: According to the SURMOUNT clinical trials, researchers observed weight loss results exceeding 20% over 72 weeks.

• Superior Appetite Control: Significantly delays gastric emptying and suppresses hunger signals more effectively than first-generation peptides.

• Cardiovascular Benefits: Data suggests significant improvements in blood pressure and lipid profiles during research cycles.

  Quick Specifications

  • Class: Dual GLP-1 & GIP Receptor Agonist

  • Format: 10mg Lyophilized Peptide

  • Administration: Once-weekly subcutaneous injection
  • Clinical Status: FDA-approved for T2DM and Obesity (commercial brand names Mounjaro/Zepbound)

  The Research Benchmark

  Tirzepatide remains the gold standard for comparing new metabolic therapies like Retatrutide. Its ability to tackle both glycemic control and adiposity makes it a foundational tool for modern obesity pharmacotherapy studies.

  Notice: This product is sold for laboratory research use only. It is not intended for human consumption outside of clinical settings.